Table I.
Association between NFKBIZ expression and clinical features of patients with bladder cancer (n=34).
| Variable | Total | Low NFKBIZ expression (n=28) | High NFKBIZ expression (n=6) | P-value |
|---|---|---|---|---|
| Sex | ||||
| Male | 25 | 22 | 3 | 0.306 |
| Female | 9 | 6 | 3 | |
| Age, years | ||||
| ≥60 | 22 | 20 | 2 | 0.154 |
| <60 | 12 | 8 | 4 | |
| Tumor size, cm | ||||
| ≥3 | 20 | 17 | 3 | 0.672 |
| <3 | 14 | 11 | 3 | |
| Multiplicity of tumor | ||||
| Single | 17 | 14 | 3 | >0.999 |
| Multiple | 17 | 14 | 3 | |
| Tumor grade | ||||
| PUNLMP, low grade | 8 | 4 | 4 | 0.018 |
| High grade | 26 | 24 | 2 | |
| Tumor stage | ||||
| Ta, T1 | 10 | 5 | 5 | 0.005 |
| T2-T4 | 24 | 23 | 1 | |
| Lymph node status | ||||
| Negative | 26 | 22 | 4 | 0.609 |
| Positive | 8 | 6 | 2 | |
| Distant metastasis | ||||
| Absent | 34 | 28 | 6 | |
| Present | 0 | 0 | 0 |
NFKBIZ, NF-κB inhibitor ζ; PUNLMP, papillary urothelial neoplasms of low malignant potential.